Regulatory alignment with U.S. Food and Drug Administration (FDA) on key elements of NOV-ERA Phase 2b study design, including novel primary ...
On April 30, 2026, Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) announced an 'End-of-Phase 2' meeting with the U.S. Food and Drug Administration (FDA) in which the agency provided critical guidance on ...
Toxicity monitoring in phase I/II clinical trials with applications at James Graham Brown Cancer Center Clinical Trials. This is an ASCO Meeting Abstract from the 2014 ASCO Annual Meeting I. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results